BridgeBio’s Infigratinib Signals Breakthrough in Pediatric Achondroplasia Trial
Published on 02/13/2026 at 11:21 | Redaktion boerse-global.de
BridgeBio Pharma announced yesterday the successful completion of the pivotal Phase 3 PROPEL 3 study evaluating Infigratinib. The data demonstrate meaningful clinical benefits in children with achondroplasia, the most common form of dwarfism. With the primary endpoint reached, a potential regulatory filing for the oral therapy moves closer to market approval.
- Strong growth: Annual growth velocity increased by 1.74 cm compared with the placebo group.
- Milestone: First statistically significant improvement in body proportionality observed.
- Safety: Well tolerated with no serious treatment-related adverse events.
- Timeline: Submissions to FDA and EMA for regulatory approval are planned for the second half of 2026.
In Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
en | US10806X1028 | BRIDGEBIO’S | boerse | 68578071 |
